Solid-Phase Synthesis of Dihydropyrans by Eu(fod)₃-Catalysed [4+2] Heterocycloaddition of Vinyl Ethers with Benzylidenepyruvic Acid Esters. Comparison with Conventional Homogeneous Liquid Phase Conditions

Stéphane Leconte, [a] Gilles Dujardin,*[a] and Eric Brown*[a]

Keywords: Solid phase synthesis / Wang resin / Hetero Diels-Alder reactions / Dihydropyrans / Reductive cleavage

The OH groups of Wang resin were esterified with benzylidenepyruvic acid (1) to give the immobilized 1-oxabutadiene 2. The latter reacted with vinyl ethers 3a-h (dienophiles) in the presence of Eu(fod)₃, and the resulting adducts 4a-h underwent reductive cleavage with LiAlH₄ to afford the dihydropyrans 5a—h in high (62 to 100%) overall yields. A similar sequence carried out under conventional homogeneous liquid phase conditions led to significantly lower yields. The endo/exo selectivity of the cycloaddition reaction was the same in both cases.

Introduction

In view of developing combinatorial chemistry, which is expected to become a powerful tool for accelerating the discovery of useful new drugs, in recent years a growing number of organic reactions have been carried out with reactants linked to insoluble polymeric carriers. Accordingly, a few examples of Diels–Alder and hetero Diels–Alder reactions performed under such heterogeneous conditions have been reported.^[1]

We describe herein the Eu(fod)₃-catalyzed [4+2] heterocycloadditions of various soluble electron-rich dienophiles with an insoluble carrier-bound 1-oxabutadiene (2) obtained by esterification of the free OH groups of Wang resin with benzylidenepyruvic acid 1 in the presence of diisopropylcarbodiimide (DIC)/DMAP (Scheme 1). Completion of this anchoring reaction was ascertained by subsequent Li-AlH₄ reduction which afforded the diol 6 in quantitative yield. The supported heterodiene 2 was treated with the dienophilic vinyl ethers 3a-h in the presence of a catalytic amount (5 mol-%) of Eu(fod)₃ in refluxing dichloromethane. Reductive cleavage of the expected supported heterocycloadducts 4a-h was then smoothly achieved by means of LiAlH₄ in ether/THF at 20 °C followed by mild hydrolysis with aqueous Na₂SO₄, and gave high overall yields^[2] of epimeric mixtures of the primary allylic alcohols endo-5a-h (major epimer) and exo-5a-h (Table). The products were found to be practically free of impurities, as evidenced from the ¹H- and ¹³C-NMR spectra. When this three-step solidphase sequence was conducted without any Eu(fod)3 catalyst in the second step, diol 6 was obtained as the sole product, which shows the failure of such uncatalyzed heterocycloaddition under solid-phase conditions. Another striking feature, readily demonstrated by the results in Table 1, is that the solid-phase cycloaddition is very endo-selective, particularly so in the case of the adducts 5a-c,e (obtained

The syntheses of the adducts **5a-h** were then carried out under conventional liquid phase conditions, as previously described. ^[3] Thus, the Eu(fod)₃-catalyzed heterocycloaddition of methyl benzylidenepyruvate **7** with the vinyl ethers **3a-h** in dichloromethane gave the epimeric adducts **8a-h**, which were in turn reduced to the allylic alcohols **5a-h** by means of LiAlH₄ in ether at room temperature. The results are displayed in Table 1. It appears that the *endolexo* selectivity is almost the same both under solid-phase and under homogeneous liquid-phase conditions. With the exception

Avenue Olivier Messiaen, F-72085 Le Mans Cedex 9, France

from vinyl ethers of primary and secondary alcohols), with *endolexo* ratios ranging from 94:6 to >97:3.

[[]a] Laboratoire de Synthèse Organique, (ESA 6011), Faculté des Sciences,

of the β-naphthyl adduct **5g**, it can be seen *that the overall* yields are substantially higher under solid-phase syntheses than under conventional homogeneous conditions. Yield increase is particularly striking in the case of the adduct **5h** (yield is 22% in liquid phase and 86% in solid phase conditions).

Table 1. Syntheses of dihydropyrans 5a-h

		synthesis 1 (%) <i>endolexo</i> rat		Liquid phase synthesis overall yield (%)endo/exo ratio		
5a 5b 5c 5d 5e 5f	92 100 92 82 100	> 97:3 96:4 >97:3 74:26 94:6 80:20 74:26	87 61 47 70 57 79	> 97:3 96:4 >97:3 75:25 96:4 80:20 80:20		
5g 5h	86	- -	22	-		

We next considered applying the above reaction schemes to other types of dienophiles of somewhat lower reactivity, such as the styrenes 9, 10, and the *O*-silyl vinyl ether 11. Starting from methyl benzylidenepyruvate 7, the epimeric *endolexo* adducts 15–17 were obtained by LiAlH₄ reduction of the intermediate ester adducts 12–14 (Scheme 2). Solid phase synthesis of 15–17 was then carried out as described above for the adducts 5a–h.

OMe

$$Ph$$
 $R = MeO_2C : endo-12$
 $R = HOCH_2 : endo-15$
 $endo-16 (+ exo)$
 $endo-17 (+ exo)$
 $endo-17 (+ exo)$

Scheme 2

The results displayed in Table 2 show that in these cases, and contrary to our observations when the vinyl ethers 3a—h were used as dienophiles, the yields of the adducts 15—17 are much lower under solid phase conditions compared with those obtained by homogeneous liquid phase syntheses. The lack of reactivity of styrenic dienophiles 9, 10 under solid-phase conditions might be due to unfavorable interactions in the *endo*-transition state between the aromatic nucleus and the matrix of the insoluble conjugate 2. In the case of the silyl enol ether 11, steric hindrance might restrict the formation of adducts 17 under solid phase conditions,

owing to the bulkiness of both possible *endo*-directing groups. Some support for this phenomenon was already given above in the case of the β -naphthyl vinyl ether 3g (Table 2).

Conclusion

The present study shows that the solid phase Eu(fod)₃-catalysed [4+2] heterocycloaddition of simple vinyl ethers may have advantages over the conventional homogeneous liquid-phase syntheses in terms of overall yields. However, the rather low "capacity" of the Wang resin is a drawback which cannot be neglected. For this reason, we are currently investigating other types of insoluble carriers which bear larger amounts of reactive OH groups than the Wang resin. From a more general point of view, our present results exemplify the efficiency of LiAlH₄ as reductive cleavage reagent of ester linkages. Indeed, the overall sequence is fully compatible with clean preparations of sensitive products.^[4]

Experimental Section

General: IR: Nicolet 5DX and Genesis (Mattson). – NMR: Bruker AC 400 (400 MHz for ¹H; 100 MHz for ¹³C). CDCl₃ was used as solvent and TMS as internal standard. – High resolution mass spectra were performed on a Varian MAT311 at the C.R.M.P.O. (Rennes).

General Experimental Procedure for Solid-Phase Syntheses: A solution of DIC (3 equiv.) in DMF (10 mL) was added at 0 °C to a suspension of commercial Wang resin (1 g; 0.8-1.1 mmol of OH groups; 1 equiv.) in a solution of benzylidenepyruvic acid 1 (3 equiv.) and DMAP (0.3 equiv.) in DMF (10 mL). After shaking for 1 h at 0 °C and 17 h at 20 °C, the mixture was filtered. The recovered resin was washed successively with CH₂Cl₂ (twice), petroleum ether, ether, acetone, CH₂Cl₂ (twice), and was dried at 20 °C. The resin was next suspended in a solution of the requisite vinyl ether (3a-h), Eu(fod)₃ (5.5 10⁻² mmol) in CH₂Cl₂ (10 mL) and the resulting mixture refluxed for 2 days with shaking. The resin was washed with CH₂Cl₂ (twice) and ether (twice). The dried resin was then added to a solution of LiAlH₄ (1 molar equiv.) in ether at 0 °C. After 1 h at 0 °C and 17 h at 20 °C, the reaction medium was hydrolyzed with saturated aqueous Na_2SO_4 (160 μL) and filtered through Celite. The solid was washed with CH2Cl2 and the combined filtrates evaporated under reduced pressure to afford the unstable dihydropyrans 5a-h, which were then analyzed by ¹H- and ¹³C-NMR spectroscopy.

Methyl 2-Ethoxy-4-phenyl-3,4-dihydro-2*H*-pyran-6-carboxylate (8a):^[5] – A Typical Procedure for the Homogeneous Syntheses of the Adducts 8a–g: Ethyl vinyl ether 3a (530 μL; 5 mmol) and the cata-

Table 2. Syntheses of dihydropyrans 15-17

Compounds	Solid phase synthesis		Liquid phase synthesis	
15 16 17	overall yield (%) 12 4 24	endolexo ratio > 97:3 - 68:32	overall yield (%) 97 63 76	endolexo ratio > 97:3 > 97:3 75:25

lyst Eu(fod)₃ (0.055 g, 5% molar) were added to a solution of methyl benzylidenepyruvate $7^{[3a]}$ (0.190 g, 1.0 mmol) in CH₂Cl₂ (5 mL) contained in a 10 mL flask equipped with a reflux condenser and a silica gel drying tube. The mixture was refluxed for 48 h, the solvent evaporated and the residue chromatographed on silica gel (ratio 40:1, eluent cyclohexane/AcOEt 90:10) to afford the adduct $8a^{[5]}$ (0.255 g, 0.97 mmol; 97%), *endolexo* ratio >99:1.

Methyl 2-Isobutoxy-3,4-dihydro-4-phenyl-2*H*-**pyran-6-carboxylate (8b):** From **3b** and **7**, oil (99%). *endolexo* ratio 98:2. – IR (film): $\tilde{v} = 1737 \text{ cm}^{-1}$, 1643. – ^{1}H NMR (CDCl₃): $\delta = 0.89$ (broad d, J = 6.6 Hz, 3 H), 0.90 (d, J = 6.5 Hz, 3 H), 1.90 (m, 1 H), 2.07 (ddd, J = 7.5, 8.3, 13.7 Hz, 1 H), 2.37 (ddd, J = 1.5, 7.2, 13.7 Hz, 1 H), 3.34 (dd, J = 6.8, 9.1 Hz, 1 H), 3.76 (dt, J = 3.1, 8.3 Hz, 1 H), 3.84 (s, 3 H), 3.88 (dd, J = 6.5, 9.1 Hz, 1 H), 5.35 (d, J = 6.4 Hz, 1 H), 6.29 (d, J = 2.9 Hz, 1 H), 7.21–7.33 (m, 5 H). – ^{13}C NMR (CDCl₃): $\delta = 19.2$, 19.3, 28.5, 35.9, 37.5, 52.2, 76.2, 100.6, 114.5, 126.7, 127.6, 128.6, 142.6, 143.0, 163.6. – MSHR: calcd. for M+290.1518 (C₁₇H₂₂O₄), found 290.1506.

Methyl 2-cyclohexyloxy-3,4-dihydro-4-phenyl-2*H*-pyran-6-carboxylate (8c): From 3c and 7, oil (99%). *endolexo* ratio > 97:3. – IR (film): $\tilde{v} = 1733$ cm⁻¹, 1643. – ¹H NMR (CDCl₃): $\delta = 1.20$ –2.10 (m, 11 H); 2.28 (dd, J = 7.4, 13.7 Hz, 1 H), 3.74 (ddd, J = 3.1, 7.1, 8.9 Hz, 1 H), 3.82 (s, 3 H); 3.86 (m, 1 H), 5.36 (d, J = 7.2 Hz, 1 H), 6.18 (d, J = 2.7 Hz, 1 H), 7.20–7.35 (m, 5 H). – ¹³C NMR (CDCl₃): $\delta = 23.1$, 23.2, 24.9, 31.0, 32.7, 35.8, 37.1, 51.5, 97.5, 113.7, 126.0, 126.8, 127.8, 141.9, 142.3, 162.8.

Methyl 2-*tert***-Butoxy-3,4-dihydro-4-phenyl-2***H***-pyran-6-carboxylate** (8d): From 3d and 7, oil (97%). *endolexo* ratio 77:23. – IR (film): $\tilde{v} = 1735 \text{ cm}^{-1}$, 1643. – ^1H NMR (CDCl₃): *endo-*8d, $\delta = 1.31$ (s, 9 H), 1.97 (ddd, J = 8.4, 9.4, 13.4 Hz, 1 H), 2.19 (dddd, J = 1.1, 1.9, 7.0, 13.4 Hz, 1 H), 3.75 (ddd, J = 2.9, 7.0, 12.8 Hz, 1 H), 3.80 (s, 3 H), 5.38 (dd, J = 1.9, 8.3 Hz, 1 H), 6.13 (dd, J = 1.0, 2.9 Hz, 1 H), 7.19–7.34 (m, 5 H); *exo-*8d, $\delta = 1.33$ (s, 9 H), 1.82 (dd, J = 2.5, 11.5 Hz, 1 H), 2.07 (m, 1 H), 3.80 (s, 3 H), 3.83 (m, 1 H), 5.65 (s, 1 H), 6.25 (dd, J = 1.5, 2.5 Hz, 1 H), 7.19–7.34 (m, 5 H). – 13 C NMR (CDCl₃): *endo-*8d, $\delta = 28.7$, 37.4, 38.3, 52.1, 95.0, 113.9, 126.6, 127.4, 128.5, 142.8, 142.9, 163.3; *exo-*8d, $\delta = 26.9$, 34.1, 36.1, 52.1, 92.1, 115.2, 126.7, 127.6, 128.6, 140.9, 143.6, 163.7. – MSHR: calcd. for M*: 290.1518 (C₁₇H₂₂O₄), found 290.1506.

Methyl 3,4-Dihydro-2-(4-hydroxybutoxy)-4-phenyl-2*H*-pyran-6-carboxylate (8e): From 3e and 7, oil (84%). *endolexo* ratio 87:13. – IR (film): $\tilde{v} = 3339 \text{ cm}^{-1}$, 1729. – ¹H NMR (CDCl₃): *endo-*8e, δ = 1.64 (m, 4 H), 1.84 (s, 1 H), 1.99 (ddd, J = 7.8, 8.8, 13.6 Hz, 1 H), 2.30 (m, 1 H), 3.62 (m, 3 H), 3.72 (ddd, J = 3.1, 7.1, 8.9 Hz, 1 H), 3.81 (s, 3 H), 4.01 (dt, J = 5.8, 9.7 Hz, 1 H), 5.15 (dd, J = 2.1, 7.6 Hz, 1 H), 6.17 (dd, J = 1.0, 2.6 Hz, 1 H), 7.15–7.32 (m, 5 H). – ¹³C NMR (CDCl₃): *endo-*8e, δ = 26.1, 29.4, 35.8, 37.4, 52.2, 62.5, 69.2, 100.1, 114.4, 126.8, 127.4, 128.5, 142.1, 142.7, 163.1; *exo-*8e, δ = 25.1, 26.8, 35.7, 37.5, 52.2, 64.9, 68.5, 99.9, 114.2, 126.8, 127.5, 128.7, 142.1, 142.7, 162.9.

Methyl 3,4-Dihydro-2-methoxy-2-methyl-4-phenyl-2*H*-pyran-6-carboxylate (8f): From 3f and 7, oil (92%). *endolexo* ratio 80:20. – IR (film): $\tilde{v} = 1724$ cm⁻¹, 1650. – ¹H NMR (CDCl₃): *endo*-8f, $\delta = 1.51$ (s, 3 H), 2.09 (d, J = 7.3 Hz, 2 H), 3.30 (s, 3 H), 3.63 (dt, J = 3.3, 7.3 Hz, 1 H), 3.83 (s, 3 H), 6.24 (d, J = 3.2 Hz, 1 H), 7.21–7.33 (m, 5 H); *exo*-8f, $\delta = 1.56$ (s, 3 H), 2.20 (m, 2 H), 3.35 (s, 3 H), 3.77 (m, 1 H), 3.81 (s, 3 H), 6.24 (d, J = 3.2 Hz, 1 H), 7.21–7.33 (m, 5 H). ¹³C NMR (CDCl₃): *endo*-8f, $\delta = 22.2$, 37.2, 38.9, 49.1, 52.2, 101.2, 113.6, 126.6, 125.7, 128.4, 142.4, 143.2, 163.3; *exo*-8f, $\delta = 22.7$, 35.7, 40.9, 49.3, 52.1, 99.6, 116.0, 126.8, 127.6, 128.7, 141.0, 143.1, 163.6.

Methyl 3,4-Dihydro-2-methoxy-2(2-naphthyl)-4-phenyl-2*H*-pyran-6-carboxylate (8g): From 3g and 7, oil (98%). endolexo ratio 80:20. – IR (film): $\tilde{v}=1731~\text{cm}^{-1}$, 1681, 1650. ^{-1}H NMR (CDCl₃): endo-8g, $\delta=2.38$ (dd, J=8.0, 13.5 Hz, 1 H), 2.56 (dd, J=7.0, 14.0 Hz, 1 H), 3.16 (s, 3 H), 3.31 (ddd, J=3.3, 7.0, 8.0 Hz, 1 H), 3.91 (s, 3 H), 6.28 (d, J=3.1 Hz, 1 H) 7.20–8.50 (m, 12 H); exo-8g, δ 1.80 (dd, J=12.4, 13.5 Hz, 1 H), 2.53 (ddd; J=1.5, 6.2, 13.6 Hz, 1 H), 3.19 (s, 3 H), 3.89 (s, 3 H), 4.01 (ddd, J=2.6, 6.1, 12.2 Hz, 1 H), 6.39 (t, J=1.8 Hz, 1 H), 7.20–8.15 (m, 12 H). ^{-13}C NMR (CDCl₃): endo-8g, $\delta=36.8$, 41.2, 50.3, 52.3, 103.0, 115.2, 123.6, 126.0, 126.3, 126.5, 126.7, 127.8, 128.0, 128.4, 128.5, 128.6, 129.5, 130.2, 132.9, 133.2, 136.5, 142.3, 142.9, 163.2; exo-8g: $\delta=36.3$, 42.8, 50.6, 52.2, 101.4, 116.4, 123.7, 125.9, 126.2, 126.4, 126.8, 127.5, 128.2, 128.4, 128.7, 133.1, 133.2, 137.3, 141.1, 142.7, 163.4. – MSHR: calcd. for M*: 374.1518 (C₂₄H₂₂O₄), found 374.1515.

Methyl 2,2-Bis(ethoxy)-3,4-dihydro-4-phenyl-2*H*-**pyran-6-carboxylate (8h):** From **3h** and **7**, oil (64%). – IR (film): $\tilde{v}=1731~{\rm cm}^{-1}$, 1648. – ¹H NMR (CDCl₃) $\delta=1.20,\,1.24$ (2t, J=7.1 Hz, 6 H), 1.86 (dd, $J=12.0,\,13.1$ Hz, 1 H), 2.38 (ddd, $J=1.3,\,6.5,\,13.2$ Hz, 1 H), 3.67 (dq, $J=6.8,\,7.0$ Hz, 2 H), 3.69 (dq, $J=7.0,\,9.8$ Hz, 2 H), 3.78 (m, 1 H), 3.82 (s, 3 H), 6.22 (dd, $J=1.4,\,2.2$ Hz, 1 H), 7.22–7.91 (m, 5 H). – ¹³C NMR (CDCl₃): $\delta=15.0,\,15.2,\,36.4,\,37.9,\,52.2,\,56.9,\,58.8,\,113.2,\,115.5,\,126.9,\,127.5,\,128.7,\,129.0,\,129.1,\,141.6,\,142.5,\,162.8.$ – C₁₇H₂₂O₅ calcd. C 66.65, H 7.24 found C 66.35, H 7.09.

Methyl 3,4-Dihydro-2-(4-methoxyphenyl)-4-phenyl-2*H*-pyran-6-carboxylate (12): From 7 and 9, solid (98%), m.p. 116 °C (Et₂O). *endolexo* ratio 100:0. – IR (film): $\tilde{v}=1716$ cm⁻¹, 1653. – ¹H NMR (CDCl₃) $\delta=1.98$ (dt, J=11.4, 13.8 Hz, 1 H), 2.34 (ddt, J=1.2, 6.4, 13.8 Hz, 1 H), 3.79 (s, 3 H), 3.83 (s, 3 H), 3.86 (m, 1 H), 5.06 (dd, J=1.2, 11.4 Hz, 1 H), 6.25 (t, J=1.2 Hz, 1 H), 6.88 (d, J=8.7 Hz, 2 H), 7.20–7.40 (m, 7 H). – ¹³C NMR (CDCl₃): $\delta=39.4$, 39.7, 52.3, 55.3, 78.7, 113.9, 114.3, 126.9, 127.2, 127.6, 128.8, 132.4, 143.2, 145.2, 159.5, 163.4. – MSHR: calcd. for M⁺: 324.1361 (C₂₀H₂₀O₄), found 324.1367. – C₂₀H₂₀O₄ calcd. C 74.05, H 6.20, found C 74.01, H 6.36.

Methyl 3,4-Dihydro-2-(2-naphthyl)-4-phenyl-2*H*-pyran-6-carboxylate (13): From 7 and 10, oil (91%). *endolexo* ratio >97:3. – IR (film): $\tilde{v}=1729~{\rm cm}^{-1}$, 1643. – $^{1}{\rm H}$ NMR (CDCl₃): *endo-13*, $\delta=2.05~{\rm (dt},J=11.5, 13.8~{\rm Hz}, 1~{\rm H}), 2.46~{\rm (tdd},J=1.8, 6.4, 13.8~{\rm Hz}, 1~{\rm H}), 3.85~{\rm (s,3~H)}, 3.91~{\rm (m,1~H)}, 5.26~{\rm (dd},J=1.8, 11.4~{\rm Hz}, 1~{\rm H}), 6.27~{\rm (t,}J=1.9~{\rm Hz}, 1~{\rm H}), 7.20–7.90~{\rm (m,12~H)};$ *exo-13*, $\delta=2.19~{\rm (m,1~H)}, 2.42~{\rm (m,1~H)}, 3.80~{\rm (m,1~H)}, 3.87~{\rm (s,3~H)}, 5.16~{\rm (dd},J=2.6, 9.3~{\rm Hz}, 1~{\rm H}), 6.30~{\rm (dd},J=1.2, 5.1~{\rm Hz}, 1~{\rm H}), 7.24–7.89~{\rm (m,12~H)}. – <math>^{13}{\rm C}$ NMR (CDCl₃): *endo-13*, $\delta=39.4$, 39.6, 52.3, 79.0, 114.6, 124.0, 125.2, 126.0, 126.1, 126.9, 127.2, 127.6, 128.0, 128.3, 128.7, 129.0, 129.1, 133.1, 133.2, 137.6, 142.9, 145.1, 163.4; *exo-13*, $\delta=36.2, 37.3, 52.3, 74.5, 112.4, 123.7–133.2, 137.7, 142.9, 143.9, 144.8, 163.3. – MSHR: calcd. for M+: 344.1423~{\rm (C_{23}H_{20}O_3)}, found 344.1422.$

Methyl 2-(tert-Butyldimethylsiloxy)-3,4-dihydro-2-(2-naphthyl)-4-phenyl-2*H*-pyran-6-carboxylate (14): From 7 and 11, oil (96%). endolexo ratio 75:25. – IR (film): $\tilde{v}=1734$ cm $^{-1}$, 1649. – 1 H NMR (CDCl $_3$): endo-14, δ = -0.32 (s, 3 H), -0.03 (s, 3 H), 0.92 (s, 9 H), 1.65 (dd, J=12.8, 13.0 Hz, 1 H), 2.51 (ddd, J=1.7, 5.6, 13.3 Hz, 1 H), 3.88 (s, 3 H), 3.95 (ddd, J=2.2, 5.6, 12.3 Hz, 1 H), 6.37 (broad t, J=1.8 Hz, 1 H), 7.13–8.47 (m, 12 H); exo-14, δ = -0.16 (s, 3 H), -0.15 (s, 3 H), 0.82 (s, 9 H), 2.21 (dd, J=11.4, 13.5 Hz, 1 H), 2.65 (ddd, J=1.4, 5.8, 11.4 Hz, 1 H), 3.09 (ddd, J=2.4, 5.7, 11.4 Hz, 1 H), 3.91 (s, 3 H), 6.17 (dd, J=1.3, 2.4 Hz, 1 H), 7.13–8.47 (m, 12 H). – 13 C NMR (CDCl $_3$): endo-14, δ = -4.5, –

4.8, 17.3, 25.0, 35.2, 43.7, 51.3, 98.5, 114.3, 123.1, 123.6, 125.3, 125.9, 126.5, 126.7, 126.8, 127.6, 127.8, 132.0, 132.1, 140.3, 140.9, 142.0, 162.5; exo-14, $\delta = -2.8$, -3.4, 16.5, 26.0, 37.3, 43.9, 52.4, 102.0, 114.5, 123.7–128.7, 133.1, 133.2, 140.4, 142.7, 143.3, 163.1. $-C_{26}H_{34}O_4Si$ calcd. C 73.38, H 7.21, found C 73.33, H 7.29.

2-[(1-tert-Butyldimethylsiloxy)vinyl]naphthalene (**11**): A solution of sodium iodide (9.4 g, 62.5 mmol) in MeCN (65 mL) was added dropwise under nitrogen to a stirred mixture of 2-acetylnaphthalene (8.5 g, 50 mmol), Et₃N (8.7 mL; 62.5 mmol), and *t*BuMe₂SiCl (9.4 g, 62.5 mmol). The mixture was stirred for 18 h at 20 °C, filtered, and the filtrate extracted with petroleum ether (3 × 50 mL). The petroleum extract was evaporated and the residue distilled under vacuum to give the unstable *O*-silyl enol ether **11** (10.3 g, 72%), b.p. (0.35 Torr) 135–140 °C. – IR (film): \tilde{v} = 1594 cm⁻¹, 1133. – ¹H NMR (CDCl₃): δ = 0.23 (s, 6 H), 1.04 (s, 9 H), 4.53 (d, *J* = 1.6 Hz, 1 H), 5.02 (d, *J* = 1.6 Hz, 1 H), 7.41–8.08 (m, 7 H). – ¹³C NMR (CDCl₃): δ = -4.60, 25.9, 91.8, 123.4, 124.3, 126.1, 126.7, 127.6, 128.5, 133.1, 133.2, 135.0, 155.8. – C₂₀H₂₀O₄ calcd. C 74.05, H 6.20, found C 74.01, H 6.36.

(2-Ethoxy-3,4-dihydro-4-phenyl-2H-pyran-6-yl)methanol (5a) from 8a: A Typical Procedure for the Homogeneous Syntheses of the Allylic Alcohols 5a-h from the Esters 8a-h: LiAlH₄ (0.071 g, 1.8 equiv.) was added portionwise to a solution of the ester 8a (0.255 g, 0.97 mmol) in anhydrous ether (20 mL), contained in a two-necked 50 mL flask equipped with a septum, a stopper and an argon inlet with ice cooling. After complete transformation of the starting material (TLC), the reaction mixture was hydrolyzed with saturated aqueous Na₂SO₄ solution (160 µL) and stirred for a few minutes. The mixture was filtered through Celite, dried (MgSO₄) and evaporated. The residue (0.277 g) was chromatographed on silica gel (ratio 1:x40, eluent cyclohexane/AcOEt from 90:10 to 70:30), to give 5a as a colourless oil (0.203 g, 0.89 mmol; 89%). endolexo ratio >98:2. - IR (film): $\tilde{v} = 3400 \text{ cm}^{-1}$, 1652, 1602, 1128. $- {}^{1}H$ NMR (CDCl₃): $\delta = 1.25$ (t, J = 7.1 Hz, 3 H), 1.64 (s, 1 H), 1.86 (m, 1 H), 2.26 (ddt, J = 1.7, 6.4, 13.2 Hz, 1 H), 3.63 (m, 2 H), 3.98 (dq, J = 7.1, 9.5 Hz, 1 H), 4.05 (dd, J = 6.3, 13.0 Hz, 1 H), 4.12 (dd, $J = 5.7, 13.0 \,\mathrm{Hz}, 1 \,\mathrm{H}), 4.87 \,\mathrm{(broad s, 1 H)}, 5.11 \,\mathrm{(dd,}\ J = 1.9,$ 9.1 Hz, 1 H), 7.19–7.31 (m, 5 H). - ¹³C NMR (CDCl₃): δ = 15.2, 37.2, 37.8, 63.0, 64.5, 100.2, 101.6, 126.5, 127.2, 128.5, 144.2, 151.4.

(3,4-Dihydro-2-isobutoxy-4-phenyl-2*H*-pyran-6-yl)methanol (5b): From 8b, oil (61%). *endolexo* ratio 96:4. – IR (film): $\tilde{v} = 3386$ cm⁻¹, 2956, 1681. – ¹H NMR (CDCl₃): $\delta = 0.90$ (d, J = 6.6 Hz, 6 H), 1.79 (m, 1 H), 1.89 (m, 2 H), 2.26 (ddt, J = 1.8, 6.7, 13.2 Hz, 1 H), 3.27 (dd, J = 6.9, 9.2 Hz, 1 H), 3.63 (m, 1 H), 3.71 (dd, J = 6.5, 9.2 Hz, 1 H), 4.05 (dd, J = 6.3, 13.1 Hz, 1 H), 4.12 (dd, J = 5.6, 13.1 Hz, 1 H), 4.88 (d, J = 0.9 Hz, 1 H), 5.08 (dd, J = 2.1, 8.6 Hz, 1 H), 7.19–7.31 (m, 5 H). – ¹³C NMR (CDCl₃): $\delta = 19.2$, 19.3, 28.5, 37.0, 37.5, 63.1, 75.9, 100.5, 101.5, 126.5, 127.2, 128.5, 144.3, 151.4. – MSHR: calcd for M⁺: 262.1569 (C₁₆H₂₂O₃), found 262.1558.

(2-Cyclohexyloxy-3,4-dihydro-4-phenyl-2*H*-pyran-6-yl)methanol (5c): From 8c, oil (47%). *endolexo* ratio > 97:3. – IR (film): \tilde{v} = 3430 cm⁻¹, 2931, 1681. – ¹H NMR (CDCl₃): δ = 0.85–2.00 (m, 11 H), 2.21 (ddt, J = 1.7, 6.4, 13.3 Hz, 1 H), 3.62–3.77 (m, 2 H), 4.04 (dd, J = 5.6, 13.0 Hz, 1 H), 4.12 (dd, J = 4.6, 13.0 Hz, 1 H), 4.85 (br. s, 1 H), 5.23 (dd, J = 2.0, 9.1 Hz, 1 H), 7.20 (m, 5 H). – ¹³C NMR (CDCl₃): δ = 23.9, 24.1, 25.6, 31.9, 33.6, 37.7, 37.9, 63.1, 76.6, 98.4, 101.4, 126.5, 127.2, 128.4, 144.4, 151.6.

(2-*tert*-Butoxy-3,4-dihydro-4-phenyl-2*H*-pyran-6-yl)methanol (5d): From 8d, oil (71%). *endolexo* ratio 75:25. – IR (film): $\tilde{v} = 3477$ cm⁻¹, 2973, 1681. – ¹H NMR (CDCl3): *endo-*5d, $\delta = 1.30$ (s, 9 H), 1.74

(dd, J = 5.9, 6.9 Hz, 1 H), 1.89 (ddd, J = 9.4, 11.2, 13.3 Hz, 1 H), 2.12 (ddt, J = 1.7, 6.6, 13.2 Hz, 1 H), 3.67 (m, 1 H), 4.04 (m, 2 H), 4.82 (broad s, 1 H), 5.31 (dd, J = 2.1, 9.4 Hz, 1 H), 7.20–7.30 (m, 5 H); *exo-5d*, δ = 1.68 (t, J = 6.2 Hz, 1 H), 1.78 (dd, J = 2.8, 10.3 Hz, 1 H), 2.01 (m, 1 H), 3.67 (m, 1 H), 4.04 (m, 2 H), 4.93 (m, 1 H), 5.38 (t, J = 3.0 Hz, 1 H), 7.20–7.30 (m, 5 H). $^{-13}$ C NMR (CDCl₃): *endo-5d* δ = 28.7, 38.4, 38.7, 63.1, 75.7, 95.1, 101.1, 126.5, 127.2, 128.5, 144.4, 151.9; *exo-5d*, δ = 28.8, 33.5, 37.0, 63.7, 74.9, 91.5, 101.4, 126.3, 127.5, 128.4, 145.3, 150.0. – MSHR: calcd. for M⁺: 262.1569 (C₁₆H₂₂O₃), found 262.1584.

[3,4-Dihydro-2-(4-hydroxybutoxy)-4-phenyl-2*H*-pyran-6-yl]methanol (5e): From 8e, oil (68%). *endolexo* ratio 80:20. – IR (film): $\tilde{v}=3360$ cm⁻¹, 1679. – ¹H NMR (CDCl₃): *endo-*5e, $\delta=1.65$ (m, 4 H), 1.86 (ddd, J=8.7, 10.2, 13.2 Hz, 1 H), 2.23 (ddt, J=1.6, 6.4, 13.2 Hz, 1 H), 2.67 (s, 1 H), 3.02 (s, 1 H), 3.61 (m, 4 H), 3.94 (m, 1 H), 4.03 (d, J=13.2 Hz, 1 H), 4.08 (d, J=13.7 Hz, 1 H), 4.87 (broad s, 1 H), 5.08 (dd, J=2.0, 8.8 Hz, 1 H), 7.17–7.30 (m, 5 H). – ¹³C NMR (CDCl₃): *endo-*5e, $\delta=26.3$, 29.4, 37.0, 37.45, 62.4, 62.8, 69.0, 100.3, 101.5, 126.5, 127.5, 128.5, 144.3, 151.6; *exo-*5e, $\delta=26.5$, 29.7, 33.5, 35.7, 62.5, 63.2, 68.5, 97.0, 102.3, 127.2, 127.5, 128.5, 144.8, 150.0 – MSHR: calcd for [M⁺ – C₄H₁₀O₂]: 188.0890 (C₁₂H₁₂O₂), found 188.0837.

(3,4-Dihydro-2-methoxy-2-methyl-4-phenyl-4*H*-pyran-6-yl)methanol (5f): From 8f, oil (86%). *endolexo* ratio 80:20. – IR (film): $\tilde{v} = 3421$ cm⁻¹, 1679. – ¹H NMR (CDCl₃): *endo-*5f, $\delta = 1.48$ (s, 3 H), 1.56 (s, 1 H), 2.00 (d, J = 8.0 Hz, 2 H), 3.32 (s, 3 H), 3.53 (dt, J = 2.4, 8.0 Hz, 1 H), 4.10 (AB, J = 7.2 Hz, 2 H), 4.91 (d, J = 2.4 Hz, 1 H), 7.20–7.32 (m, 5 H); *exo-*5f, $\delta = 1.48$ (s, 3 H), 1.65 (t, J = 12.8 Hz, 1 H), 2.16 (ddd, J = 1.5, 6.2, 13.4 Hz, 1 H), 3.33 (s, 3 H), 3.66 (ddd, J = 1.6, 6.3, 12.2 Hz, 1 H), 4.06 (d, J = 6.6 Hz· 1 H), 4.14 (d, J = 6.6 Hz, 1 H), 4.97 (broad s, 1 H), 7.20–7.32 (m, 5 H). – ¹³C NMR (CDCl₃): *endo-*5f, $\delta = 22.8$, 37.9, 40.0, 49.7, 63.8, 100.7, 101.7, 127.1, 128.2, 129.2, 145.3, 152.5; *exo-*5f, $\delta = 23.5$, 35.6, 42.4, 49.6, 64.0, 99.5, 103.3, 127.3, 127.9, 129.1, 145.5, 150.7. – MSHR: calcd for M⁺: 234.1256 (C₁₄H₁₈O₃), found 234. 1240.

[3,4-Dihydro-2-methoxy-2-(2-naphthyl)-4-phenyl-2*H*-pyran-6-yll-methanol (5g): From 8g, oil (79%). *endolexo* ratio 80:20. – IR (film): $\tilde{v} = 3386$ cm⁻¹, 1681. – ¹H NMR (CDCl₃): *endo*-5g, $\delta = 2.06$ (t, J = 6.4 Hz, 1 H), 2.29 (dd, J = 9.2, 13.3 Hz, 1 H), 2.51 (ddd, J = 0.8, 6.3, 13.3 Hz, 1 H), 3.10 (m, 1 H), 3.15 (s, 3 H), 4.34 (t, J = 6.1 Hz, 2 H), 5.00 (d, J = 2.2 Hz, 1 H), 7.17–8.06 (m, 12 H); *exo*-5g, $\delta = 1.76$ (ddd, J = 12.3, 13.5 Hz, 1 H), 2.20 (t, J = 6.4 Hz, 1 H), 2.46 (dddd, J = 1.6, 6.0, 13.7 Hz, 1 H), 3.20 (s, 3 H), 3.90 (ddd, J = 1.5, 5.9, 12.2 Hz, 1 H), 4.31 (m, 2 H), 5.15 (broad s, 1 H), 7.17–8.06 (m, 12 H). – ¹³C NMR (CDCl₃), *endo*-5g, $\delta = 36.2$, 41.9, 50.2, 63.3, 102.2, 102.7, 123.7, 128.4, 132.9, 133.1, 137.0, 144.2, 151.4; *exo*-5g, $\delta = 35.6$, 43.7, 50.3, 63.5, 100.8, 103.4, 123.7–128.4, 133.0, 133.1, 138.1, 144.2, 149.9. – MSHR: calcd. for M⁺: 346.1563 (C₂₃H₂₂O₃), found 346.1557.

(2,2-Diethoxy-3,4-dihydro-4-phenyl-2*H*-pyran-6-yl)methanol (5h): From 8h, oil (34%). – IR (film): $\tilde{v}=3465$ cm⁻¹, 1681. – ¹H NMR (CDCl₃): $\delta=1.21$ and 1.22 (2t, J=7.0, 7.0 Hz, 6 H), 1.77 (dd, J=12.0, 12.9 Hz, 1 H), 2.20 (s, 1 H), 2.34 (ddd, J=1.3, 6.3, 12.9 Hz, 1 H), 3.62 (2q, J=6.9, 6.9 Hz, 4 H), 3.69 (m, 1 H), 4.07 (d, J=13.2 Hz, 1 H), 4.12 (d, J=13.2 Hz, 1 H), 4.96 (broad s, 1 H), 7.19-7.33 (m, 5 H). ¹³C NMR (CDCl₃): $\delta=15.1$, 15.2, 37.1, 37.4, 56.3, 58.3, 62.7, 102.4, 112.7, 126.5, 127.3, 128.51, 144.0, 150.3. – MSHR: calcd. for M⁺: 278.1518 (C₁₆H₂₂O₄), found 278.1536.

[3,4-Dihydro-2-(4-methoxyphenyl)-4-phenyl-2H-pyran-6-yl]methanol (15): From 12, oil (99%). *endolexo* ratio >98:2. – IR (film): \tilde{v} =

3367 cm⁻¹, 1673. – ¹H NMR (CDCl₃): δ = 1.91 (dt, J = 11.5, 13.5 Hz, 1 H), 2.14 (m, 1 H), 2.25 (ddd, J = 1.7, 6.2, 13.6 Hz, 1 H), 3.74 (m, 1 H), 3.77 (s, 3 H), 4.04 (dd, J = 6.6, 13.0 Hz, 1 H), 4.14 (dd, J = 4.8, 13.0 Hz, 1 H), 4.93 (broad s, 1 H), 4.99 (dd, J = 1.5, 11.5 Hz, 1 H), 6.86–7.33 (m, 9 H). – ¹³C NMR (CDCl₃): δ = 39.1, 40.1, 55.2, 63.3, 78.0, 101.4, 113.8, 125.3–128.5, 133.1, 144.8, 153.9, 159.4.

[3,4-Dihydro-2-(2-naphthyl)-4-phenyl-2*H***-pyran-6-yl|methanol (16):** From **13**, oil (69%). *endolexo* ratio >97:3. – IR (film): $\tilde{v}=3401$ cm⁻¹, 1673. – ¹H NMR (CDCl₃): *endo-***16**, $\delta=1.96$ (t, J=5.6 Hz, 1 H), 2.04 (m, 1 H), 2.40 (ddt, J=1.7, 6.2, 13.6 Hz, 1 H), 3.82 (ddd, J=1.2, 6.1, 11.3 Hz, 1 H), 4.13 (m, 1 H), 4.23 (dd, J=4.5, 13.1 Hz, 1 H), 5.01 (broad s, 1 H), 5.23 (dd, J=1.5, 11.5 Hz, 1 H), 7.19–7.86 (m, 12 H). – ¹³C NMR (CDCl₃): *endo-***16**, $\delta=35.8$, 38.3, 63.6, 73.8, 99.2, 124.0–128.6, 133.1, 133.3, 138.6, 145.5, 154.1; *exo-***16**, $\delta=39.1$, 40.3, 63.4, 78.5, 101.8, 124.0–128.6, 133.0, 133.2, 138.4, 144.7, 153.9. – MSHR: calcd for M⁺: 316.1463 (C₂₂H₂₀O₃), found 316.1457.

[2-(tert-Butyldimethylsiloxy)-3,4-dihydro-2-(2-naphthyl)-4-phenyl- 2H-pyran-6-yl] methanol (17): From **14**, oil (79%). *endolexo* ratio 75:25. – IR (film): $\tilde{\mathbf{v}} = 3411 \, \mathrm{cm}^{-1}$, 1712. – ¹H NMR (CDCl₃): *endo-* **17**, $\delta = -0.27$ (s, 3 H), 0.01 (s, 3 H), 0.96 (s, 9 H), 1.65 (t, $J = 12.7 \, \mathrm{Hz}$, 1 H), 1.87 (t, $J = 6.5 \, \mathrm{Hz}$, 1 H), 2.44 (ddd, J = 1.6, 5.2, 13.2 Hz, 1 H), 3.84 (m, 1 H), 4.27 (m, 2 H), 5.14 (broad s, 1 H), 7.18–8.05 (m, 12 H); *exo-***17**, $\delta = -0.17$ (s, 3 H), 0.11 (s, 3 H), 0.84

(s, 9 H), 1.97 (t, J=6.6 Hz), 1 H), 2.15 (dd, J=11.8, 13.1 Hz, 1 H), 2.58 (ddd, J=1.3, 5.2, 13.2 Hz, 1 H), 2.95 (m, 1 H), 4.10–4.30 (m, 2 H), 4.94 (broad s, 1 H), 7.18–8.05 (m, 12 H). $^{-13}$ C NMR (CDCl₃): *endo-17*, $\delta=-3.4$, -3.4, 18.3, 26.0, 35.1, 45.9, 63.7, 99.0, 102.3, 123.7–128.6, 132.9, 133.0, 142.0, 144.5, 150.4; *exo-17*, $\delta=-3.1$, -2.5, 17.9, 25.8, 36.6, 45.1, 63.3, 101.5, 101.8, 123.7–128.6, 141.0, 144.1, 152.0. – MSHR: calcd. for M⁺: 446.2277 (C₂₅H₃₄O₃Si), found 446.2268.

^{[1] [1}a] S. Booth, P. H. H. Hermkens, H. C. J. Ottenheijm, D. C. Rees, *Tetrahedron* **1998**, *54*, 15385–15443. –[1b] R. C. D. Brown, *J. Chem. Soc. Perkin Trans. 1.* **1998**, 3293–3320 (reviews). – [1e] G. J. Kuster, H. W. Scheeren, *Tetrahedron Lett.* **1998**, *39*, 3613–3616.

^[2] The Wang resin (Lancaster) contained from 0.8 to 1.1 mmol of OH groups per gram. We used the latter value when calculating the overall yields of the syntheses of *endolexo-5a-h*.

^{[3] [3}a] G. Dujardin, S. Rossignol, E. Brown, *Tetrahedron* **1994**, *50*, 9037–9050. – [3b] E. Brown, G. Dujardin, M. Maudet, *Tetrahedron* **1997**, *53*, 9679–9694. – [3c] G. Dujardin, S. Rossignol, E. Brown, *Synthesis*, **1998**, 763–770.

^[4] To the best of our knowledge, LiAlH₄ has only been reported for reductive cleavage of supported amides and carbamates into amines. See for instance: C. Y. Ho, M. J. Kukla, *Tetrahe-dron Lett.* 1997, 38, 2799–2302.

 ^[5] D. L. Boger, K. D. Robarge, J. Org. Chem. 1988, 53, 3373–3377.
 Received June 1, 1999
 [O99324]